Acrivon Therapeutics, Inc.
Calidad de datos: 83%
ACRV
Nasdaq
Manufacturing
Chemicals
$1.56
▲
$0.03
(1.63%)
Cap. Mercado: 60.25 M
Precio
$1.56
Cap. Mercado
60.25 M
Rango del Día
$1.44 — $1.59
Rango de 52 Semanas
$1.05 — $3.56
Volumen
565,613
Apertura $1.48
Promedio 50D / 200D
$1.63
4.58% below
Promedio 50D / 200D
$1.75
11.12% below
Quick Summary
Puntos Clave
Negative free cash flow of -65.33 M
Crecimiento
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
-57.36%
Below sector avg (-53.41%)
ROIC-48.23%
Net MarginN/A
Op. MarginN/A
Seguridad
Debt / Equity
N/A
Current Ratio8.75
Interest CoverageN/A
Valoración
PE (TTM)
-0.77
Above sector avg (-1.48)
P/B Ratio0.47
EV/EBITDAN/A
Dividend YieldN/A
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -0.8 | -1.5 |
| P/B | 0.5 | 1.6 |
| ROE % | -57.4 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -77.91 M |
| ROE | -57.36% | ROA | -51.27% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -65.33 M |
| ROIC | -48.23% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 8.75 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 115.47 M | Tangible Book Value | 128.60 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.77 | Forward P/E | N/A |
| P/B Ratio | 0.47 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -108.44% | ||
| Market Cap | 60.25 M | Enterprise Value | 24.84 M |
| Per Share | |||
| EPS (Diluted TTM) | -2.02 | Revenue / Share | N/A |
| FCF / Share | -1.69 | OCF / Share | -1.64 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 83.86% |
| SBC-Adj. FCF | -80.63 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net Income | -77.91 M | -80.56 M | -60.39 M | -31.17 M |
| EPS (Diluted) | -2.02 | -2.38 | -2.74 | -7.56 |
| Gross Profit | — | — | — | — |
| Operating Income | -84.11 M | -89.20 M | -67.10 M | -32.66 M |
| EBITDA | — | — | — | — |
| R&D Expenses | 59.99 M | 63.99 M | 46.02 M | — |
| SG&A Expenses | — | — | — | — |
| D&A | — | — | — | — |
| Interest Expense | — | — | — | — |
| Income Tax | 0.0 | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total Assets | 129.72 M | 196.59 M | 138.27 M | 181.23 M |
| Total Liabilities | 17.20 M | 19.80 M | 17.07 M | 10.75 M |
| Shareholders' Equity | 112.52 M | 176.79 M | 121.20 M | 170.48 M |
| Total Debt | — | — | — | — |
| Cash & Equivalents | 41.50 M | 39.82 M | 36.02 M | 29.52 M |
| Current Assets | 120.45 M | 181.63 M | 129.69 M | 132.10 M |
| Current Liabilities | 15.66 M | 17.21 M | 13.30 M | 6.52 M |
{"event":"ticker_viewed","properties":{"ticker":"ACRV","listing_kind":"stock","pathname":"/stocks/acrv","exchange":"Nasdaq","country":"US"}}